Effects of continuous erythropoietin receptor activator (CERA) in kidney transplant recipients

C. Esposito, M. Abelli, G. Sileno, C. Migotto, M. Torreggiani, N. Serpieri, N. Maggi, V. Esposito, F. Grosjean, M. L. Scaramuzzi, F. Montagna, A. D. Canton

Research output: Contribution to journalArticlepeer-review


Erythropoietin-stimulating agents (ESAs) are commonly used to treat anemia in kidney transplant recipients (KTRs). Since 2007, continuous erythropoietin receptor activator (CERA) has been one of the newest recombinant ESAs to treat anemia in dialysis and nondialysis patients with chronic kidney disease. The efficacy of CERA to manage anemia has not been extensively evaluated in KTRs. We evaluated safety, efficacy, and satisfaction among KTRs treated with CERA. We enrolled 19 anemic KTRs (60 ± 9.3 y) who were treated with short-acting ESA for 13 g/dL. No significant differences were observed in serum iron and creatinine between short-acting ESA and CERA throughout the study. The questionnaires showed better compliance to CERA treatment with reduced pain at the injection site, which led subjects to prefer CERA to short-acting ESA. In summary, CERA showed better control of anemia compared with short-acting ESA. It was preferred by the majority of patients, mainly because of the reduced number of monthly injections. Our results demonstrated CERA to be effective, safe, and well tolerated in the management of anemia in KTRs.

Original languageEnglish
Pages (from-to)1916-1917
Number of pages2
JournalTransplantation Proceedings
Issue number7
Publication statusPublished - Sep 2012

ASJC Scopus subject areas

  • Surgery
  • Transplantation


Dive into the research topics of 'Effects of continuous erythropoietin receptor activator (CERA) in kidney transplant recipients'. Together they form a unique fingerprint.

Cite this